Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this review, researchers explore various treatment options for alopecia, focusing on nano-drug delivery systems using plant-based substances, which are potentially effective and less harmful than current treatments, while also highlighting emerging trends such as 3D bioprinting and plant extracts for future therapies.

This opinion article reviews various pathways through which onabotulinumtoxinA might work in medical treatments, highlighting applications beyond muscle paralysis, including pain inhibition and potential effects on hair loss and cancer cell apoptosis.

This study demonstrated that α-phellandrene promotes dermal papilla cell proliferation through a cAMP-mediated pathway and upregulates VEGF expression, suggesting its potential use in hair loss prevention.

This study found that LHE may prevent and reverse testosterone-induced prostatic hyperplasia, supporting the traditional use of Kigelia africana for some reproductive system disorders.

This study reviewed evidence for six minimally invasive treatments for androgenetic alopecia, finding consistent support for platelet-rich plasma and topical finasteride, while other options like microneedling and intradermal dutasteride showed promise but need further and standardized research.

This review summarizes recent advances in alopecia management, focusing on combining synthetic and herbal therapies with innovative drug delivery systems like nanocarriers to enhance effectiveness and reduce side effects, while noting challenges with skin penetration and bioavailability.

This review discusses the off-label use of SSRIs to manage inappropriate sexual behavior in elderly dementia patients and highlights the unclear risk of post-SSRI sexual dysfunction, noting a need for high-quality clinical trials.

This retrospective pharmacovigilance study identified 34 drugs, including finasteride and dutasteride, that may be associated with sexual dysfunction, with a higher risk observed in males aged 31-45.

This review found that 5α-reductase inhibitors (such as finasteride and dutasteride) effectively reduce prostate size and stabilize hair loss but are associated with sexual dysfunction; they remain essential treatments for BPH and androgenic alopecia, requiring tailored risk-benefit assessments.

This review analyzed clinical trials and guidelines on 5-α-reductase inhibitors (5-ARIs) and found these drugs significantly improve urinary symptoms in BPH and stabilize hair loss in androgenic alopecia, but may cause sexual dysfunction and gynecomastia.

In this review, 5α-reductase inhibitors like finasteride and dutasteride were found to significantly reduce prostate volume and stabilize hair loss, but they also carry risks of sexual dysfunction, necessitating careful patient evaluation and monitoring.

In this review, the researchers reported that 5α-reductase inhibitors demonstrated neuroprotective effects and reduced dyskinesias in animal models of Parkinson's disease, suggesting their potential for repurposing to manage symptoms in men with PD.

This study found that a combination of probiotic strains of Lactiplantibacillus administered over 16 weeks reduced the number and density of telogen hairs in individuals with androgenic alopecia, while increasing the abundance of Lactobacillus in their gut microbiota.

This study found that platelet-rich plasma therapy increased hair density in androgenetic alopecia and improved hair regrowth in chronic plaque alopecia, with better results when combined with minoxidil rather than finasteride.

This study found that the topical Shen Bai hair growing decoction may improve androgenetic alopecia in mice by suppressing TNF-α and IL-6 levels, enhancing follicle density, and reducing apoptosis.

This article discusses a trial evaluating patient satisfaction with the TH07 treatment for androgenetic alopecia but reports no clinical results.

This review found that both finasteride and dutasteride are effective for treating hair loss in men with androgenetic alopecia, with dutasteride showing higher efficacy, but noted unclear clinical significance regarding potential negative impacts on reproduction, including possible sexual dysfunction and effects on spermatogenesis.

This review discusses the pharmacology of 5-alpha reductase inhibitors, their expanding clinical indications beyond benign prostatic hyperplasia, and notes unresolved claims about their potential role in SARS-CoV-2.

This study identified two potent 5α-reductase inhibitors from Tectona grandis leaves, and suggests that ethanol is a preferable solvent for extracting these compounds, which are potential ingredients for hair loss treatments.

This review provides an in-depth examination of the efficacy and safety of finasteride and dutasteride, commonly used for treating benign prostatic hyperplasia and male androgenetic alopecia.

In this narrative review, researchers reported that oral finasteride significantly improved hair count and density in male androgenetic alopecia but had higher systemic exposure and potential side effects compared to topical formulations, which provided similar efficacy with lower systemic DHT suppression.

This study conducted a meta-analysis and found that men with both frontal and vertex male pattern baldness have a slightly increased risk of developing prostate cancer, though most data was from Caucasian populations and effect modification by genetic variations was not assessed.

This study discusses the potential of topical retinoids, vitamin A derivatives, to improve treatment outcomes for androgenetic alopecia by promoting hair growth through extending the anagen phase and stimulating follicular activity, offering a promising approach when combined with existing therapies.

This study found that finasteride and minoxidil act as hormone disruptors in mice, with finasteride having a more significant association with reproductive injuries, such as damage to the epididymis and reduced semen volume.

This study investigated the effects of GFC with FGF5s and NMN at a depth of 0.8 mm using a microneedle for treating hair loss, but the abstract provides no measurable results.

This study found that finasteride significantly promoted hair growth compared to placebo in male patients with androgenic alopecia, but also noted a high incidence of sexual side effects.

In this retrospective study at Toyama University Hospital, amoxapine was reported to significantly improve semen volume, sperm concentration, and total sperm count in 17 men with ejaculatory disorders, with no observed side effects over an average of 13 months of therapy.

This review discusses the role of dihydrotestosterone in benign prostatic hyperplasia and reports no new results; the authors highlight 5alpha-reductase inhibitors as a well-established treatment option.

This review highlights that sexual dysfunction associated with 5-alpha-reductase inhibitors is recognized in clinical literature, with erectile dysfunction being the most common adverse effect, followed by ejaculatory dysfunction and decreased libido.

In this systematic review, dutasteride may be more effective than finasteride for hair growth in men with androgenetic alopecia, but the comparative magnitude of this effect is highly uncertain.